Drug shown to reduce new attacks/symptom progression in some patients
In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.
Three studies conducted by an international team of researchers, which included Amit Bar-Or and Douglas Arnold from the Montreal Neurological Institute and Hospital of McGill University, have discovered that ocrelizumab can significantly reduce new attacks in patients with relapsing MS, as well as slow the progression of symptoms caused by primary progressive MS.
In one study, 732 patients with primary progressive MS were randomized on a 2:1 ratio to receive either ocrelizumab, a humanized monoclonal antibody that depletes CD20+ B cells, or a placebo.
The proportion of patients with 12-week confirmed disability progression was 39.3 per cent with the placebo versus 32.9 per cent with ocrelizumab. After 24 weeks, the proportion with confirmed disability progression was 35.7 per cent with placebo versus 29.6 per cent with ocrelizumab. By week 120, timed 25-foot walk worsened by 55.1 per cent for placebo versus 38.9 per cent for ocrelizumab. Patients given ocrelizumab were also found to have fewer new brain lesions and less brain volume loss than those given the placebo.
Researchers also tested ocrelizumab in two separate studies of patients with relapsing remitting MS, one a group of 821 and the other 835. In both studies, patients were randomized on a 1:1 ratio to receive either ocrelizumab or an already established treatment for relapsing MS: subcutaneous interferon-beta, injected three times weekly. Compared to the placebo, relapse rates in patients given ocrelizumab were 46-per-cent lower in one study and 47-per-cent lower in the other. Ocrelizumab was found to reduce the risk of disability progression after 12 weeks and 24 weeks, and reduced the number of new brain lesions.
The study noted that infusion-related reactions occurred in 34.3 per cent of ocrelizumab-treated patients. Serious infections were not more frequent with ocrelizumab compared to the interferon (1.3 versus 2.9 per cent respectively). Malignancies occurred in four ocrelizumab-treated patients and in two interferon-treated patients. Further observation is required to determine the long-term safety of ocrelizumab.
“The results in patients with relapsing remitting MS not only demonstrate very high efficacy against relapses, but also underscore the important emerging role of B cells of the immune system in the development of relapses,” says Bar-Or. “While the results in patients with primary progressive MS are more modest, they nonetheless represent the very first successful trial in such patients, a breakthrough as primary progressive MS now transitions from a previously untreatable condition to one that can be impacted by therapy. It is an important step forward in the field.”
These studies, funded by Roche, were published in the New England Journal of Medicine on Dec. 21, 2016.
MS in Canada
Canada has one of the world’s highest rates of MS – about 1,100 new cases each year. Some 50,000 Canadians have MS, and more than one-in-five patients are in Quebec. MS is one of the most common neurological diseases among young Canadians. Children as young as two can develop the disease. It typically strikes people in their prime years, between 15 and 40. Women are twice as likely as men to contract MS.
Learn more: Breakthrough in MS treatment
Receive an email update when we add a new MULTIPLE SCLEROSIS article.
The Latest on: Multiple sclerosis
via Google News
The Latest on: Multiple sclerosis
- Chronic inflammation in multiple sclerosis — seeing what was always thereon August 16, 2019 at 4:15 am
Activation of innate immune cells and other compartmentalized inflammatory cells in the brains and spinal cords of people with relapsing–remitting multiple sclerosis (MS) and progressive MS has been ...
- Vegetable-rich Diet may Ease Fatigue, Boost Good Cholesterol Levels in Multiple Sclerosis Patientson August 16, 2019 at 3:10 am
Eating a diet containing plenty of fruits and vegetables can lower fatigue in multiple sclerosis (MS) patients by raising good cholesterol levels, reports a new study. Higher levels of blood ...
- Four women now in remission from multiple sclerosis thanks to experimental treatmenton August 15, 2019 at 9:19 pm
Two years ago we met Chelsea Piszczek just before she went to Chicago to undergo HSCT or Hematopoietic Stem Cell Transplantation for her aggressive Multiple Sclerosis. Dr. Richard Burt at Northwestern ...
- Vegetable-rich diet lowers fatigue in multiple sclerosis patients by raising good cholesterolon August 15, 2019 at 12:36 pm
Higher levels of blood high-density lipoprotein (HDL) -- or good cholesterol -- may improve fatigue in multiple sclerosis patients, according to a new study. The pilot study, which investigated the ...
- Selma Blair looks strong as she models long coat from The Row amid multiple sclerosis battleon August 15, 2019 at 7:09 am
Selma Blair has been staying strong as she fights multiple sclerosis. So the star treated herself to something new, which she showed off on Instagram Thursday. The Hellboy actress, 47, looked chic as ...
- 'Brain stiffening' that 'triggers multiple sclerosis' could be reversedon August 14, 2019 at 6:00 am
Brains get stiffer with old age, scientists have discovered in breakthrough that could lead to new treatments for multiple sclerosis. University of Cambridge researchers found the brain tissue of rats ...
- Progressive multiple sclerosis: from pathophysiology to therapeutic strategieson August 9, 2019 at 9:38 am
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that involves demyelination and axonal degeneration. Although substantial progress has been made in drug ...
- Forgotten immune cells protective in mouse model of multiple sclerosison August 9, 2019 at 6:29 am
A seldom-studied class of immune cells may reduce the friendly fire that drives autoimmune disease, according to a new study by researchers at the Stanford University School of Medicine. Stimulating ...
- Global Primary Progressive Multiple Sclerosis Treatment Market 2019- F. Hoffmann-La Roche Ltd., Genzyme Corporation, Glialogix, Inc.on August 8, 2019 at 9:54 pm
Aug 09, 2019 (Eon Market Research via COMTEX) -- The global market for Primary Progressive Multiple Sclerosis Treatment has been analyzed in an in-depth market research report recently added to the ...
via Bing News